Celgene Corporation (NASDAQ: CELG) is a manufacturer of drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major products are THALOMID (thalidomide), which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum ("ENL"), as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and REVLIMID (lenalidomide), for which the company has received FDA and EMEA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. REVLIMID is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Both THALOMID and REVLIMID are sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Celgene also receives royalties from Novartis Pharma AG on sales of the entire RITALIN family of drugs, which are widely used to treat Attention Deficit Hyperactivity Disorder (ADHD).
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
Latest FEC Datacovers through committee's December 31, 2012 filing.
Summaryoverview of the committee's finances
- Total Raised:
- Total Spent:
- Cash on Hand:
Standardized Donation Informationcovers roughly through Q4 2012. may lag behind FEC section above, as donors and industries are identified by hand.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Celgene Corp
Names of Lobbyists
Firm Hired Amount Celgene Corp $2,185,000
Most Frequently Disclosed Lobbying Issues
- Health Issues,
Most Frequently Disclosed Bills
Bill No. Title H.R.2672 Preserving Access to Orphan Drugs Act of 2011 S.1423 Preserving Access to Orphan Drugs Act of 2011 H.R.1249 America Invents Act S.23 Patent Reform Act of 2011 S.3187 Food and Drug Administration Safety and Innovation Act
RegulationsMentioned in 18 dockets; Submitted to 3 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Celgene Corp" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Celgene Corp
Mentions in Document Text
View all mentions data for Celgene Corp
- Toggle 1 FDA Amendments to Sterility Test Requirements for Biological Products 2011
- Toggle 1 FDA Advisory Committee, Workshops, and Conferences Notices Various Meeting Notices (eg., Task Force Meeting, etc.) 2012
- Toggle 1 HHS Guidance on Exculpatory Language in Informed Consent, Draft 2011
- Toggle 1 CMS Medicare, Medicaid, Children's Health Insurance Programs; Transparency Reports and Reporting of Physician Ownership or Investment Interests (CMS-5060-P) 2011
- Toggle 1 Addition of ortho-Nitrotoluene; Community Right-to-Know Toxic Chemical Release Reporting 2012
- Toggle 1 EPA None Unknown
- Toggle 1 FTC Early Termination of Waiting Period under Premerger Rules 2011
- Toggle 1 FDA Risk Evaluation and Mitigation Strategy Assessments: Social Science Methodologies to Assess Goals Related to Knowledge; Public Workshop; Issue Paper 2012
- Toggle 1 NHTSA Environmental Impact Statement for Corporate Average Fuel Economy (CAFE)Standards, Model Years 2017-2025 2011
- Toggle 1 FDA Set Tolerance Levels for Polycyclic Aromatic Hydrocarbons in Seafood 2011
Federal Spending3 grants
Federal grants, contracts and loans are reported by federal agencies using the FPDS and FAADS systems. The data is made available to the public at USASpending.gov. Please note that the completeness and quality of the data varies greatly by agency.
Only grants, contracts and loans with amounts over $1 million are shown.
Because company names are not reported in a standardized manner, we cannot reliably determine the company receiving the contract or award. The results shown here are based on a search for the company name. Individual records may be missed or erroneously included because of name variations. For more information, please see our federal spending methodology page.
Note: Company names in federal spending data are not standardized. The table below is included only as a sample of what is available in the data and has not been reviewed for accuracy or completeness. To investigate the data further, use the links at the bottom of the table.
|Celgene Corporation||2012||Defense Advanced Research Projects Agency (Darpa)||LARGE-SCALE PRODUCTION OF HSC-DERIVED,GENE-MODIFIED RED BLOOD CELLS||$7,489,743|
|Celgene Corporation||2011||Dept Of The Air Force||TAS::57 3600::TAS"Large-Scale Human Placenta Progenitor Cell-Derived Erythrocyte Production - Continuous Red Blood Cell Production"||$3,687,247|
|Celgene Corporation||2011||Dept Of The Air Force||TAS::57 3600::TAS "Large-Scale Human Placenta Progenitor Cell-Derived Erythrocyte Production - Continuous Red Blood Cell Production"||$1,400,000|